RxSight, Inc. (RXST) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

42/ 100

GoAI Score

Hold

Valuation

57

Fair Value

Sentiment

69

Bullish

Risk

70

High Risk

Momentum

22

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Medical - Devices
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $4.85

$4.68$4.86

52-week range

Current $4.85

$4.48$16.74

Open: $4.725
Previous close: $4.80
Volume: 938.3K
Market cap: 200.77M USD
50-day average: $5.9138; -17.99% below average
200-day average: $6.812; -28.80% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 420.14M USD
P/E (TTM): -4.29×
P/B (TTM): 0.76×
P/S (TTM): 1.57×
EV / EBITDA: -11.81×
Earnings yield: -9.08%
Free cash flow yield: -4.51%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 77.50%
Operating margin: -43.20%
Net margin: -36.80%
Return on equity: -14.13%
Return on assets: -12.49%
Return on invested capital: -16.81%

Financial health

Debt / equity: 0.04×
Current ratio: 10.95×
Altman Z-score: -0.64
Piotroski F-score: 2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

134.48M USD-3.89%

Operating income

−48.19M USD-30.75%

Net income

−38.94M USD-41.84%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	134.48M USD	139.93M USD	89.08M USD	49.01M USD	22.59M USD
Cost of goods sold	31.47M USD	40.98M USD	35.31M USD	27.68M USD	18.08M USD
Gross profit	103.01M USD	98.94M USD	53.77M USD	21.33M USD	4.52M USD
Research and development	38.55M USD	34.37M USD	29.05M USD	25.98M USD	24.5M USD
Selling, general, and administrative	112.65M USD	101.43M USD	74.8M USD	58.67M USD	32.81M USD
Operating expenses	151.2M USD	135.8M USD	103.85M USD	84.65M USD	57.3M USD
Interest income	2.51M USD	9.47M USD	6.57M USD	1.52M USD	54K USD
Interest expense	40K USD	21K USD	3.31M USD	4.95M USD	3.68M USD
Depreciation and amortization	3.27M USD	3.62M USD	4.24M USD	4.02M USD	3.99M USD
Operating income	−48.19M USD	−36.86M USD	−50.09M USD	−63.32M USD	−52.79M USD
Net income	−38.94M USD	−27.46M USD	−48.61M USD	−66.76M USD	−48.69M USD

Company facts updated Oct 9, 2026.

Earnings

EPS beat rate: 82%; 9 beats, 2 misses, 0 met estimates
Average EPS surprise: +14.34%; 11 comparable reports
Latest EPS result: -0.29; Estimate -0.33 · Beat by 11.95%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.31

50.72% upside

Past 12 months12-month forecastHigh $11.00Average $7.31Low $5.50

Rating distribution

12 ratings

Strong buy00%

Buy325%

Hold758%

Sell217%

Strong sell00%

Recent analyst actions

11 institutions

RXST news

defenseworld.netOct 6, 2026

Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)

RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength…

Read source

defenseworld.netOct 6, 2026

RxSight (NASDAQ:RXST) and Organigram Global (NASDAQ:OGI) Financial Survey

RxSight (NASDAQ: RXST - Get Free Report) and Organigram Global (NASDAQ: OGI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on…

Read source

defenseworld.netSep 25, 2026

RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical Analysis

Cerus (NASDAQ: CERS - Get Free Report) and RxSight (NASDAQ: RXST - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of…

Read source

defenseworld.netSep 8, 2026

85,838 Shares in RxSight, Inc. $RXST Purchased by Corient Private Wealth LP

Corient Private Wealth LP bought a new stake in shares of RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,838 shares of…

Read source

defenseworld.netSep 3, 2026

BlackRock Inc. Purchases Shares of 5,790,408 RxSight, Inc. $RXST

BlackRock Inc. acquired a new stake in RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired…

Read source

globenewswire.comAug 26, 2026

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at…

Read source